Annuncio • 2h
Vatech Completes Full-Portfolio Eu Medical Device Regulation Certification Covering All Dental Imaging Models and 2026 Model Launches Vatech announced the completion of EU Medical Device Regulation (MDR; Regulation (EU) 2017/745) certification across its entire dental imaging portfolio — covering all existing commercial models and every newly launched 2026 model. The certifying body is DNV Product Assurance AS, a Notified Body designated under EU MDR. Vatech maintained its full product lineup without reduction and secured certification for all newly launched 2026 models — including premium models — through a single conformity assessment. All models newly launched in 2026 — including the premium Green X 21, Green X Plus, Green X 12 Plus, and Green X 12 SE — are included within the certified scope. With regulatory clearance already secured across multiple major jurisdictions, and EU MDR certification now in place, these solutions are available for immediate European distribution from the moment they launch — with no post-launch certification gap and no interruption to patient care. Annuncio • May 07
Value Added Technology Co., Ltd. to Report Q1, 2026 Results on May 12, 2026 Value Added Technology Co., Ltd. announced that they will report Q1, 2026 results on May 12, 2026 New Risk • Mar 22
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.3% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (9.4% net profit margin). Reported Earnings • Mar 21
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: EPS: ₩2,701 (down from ₩3,712 in FY 2024). Revenue: ₩426.4b (up 11% from FY 2024). Net income: ₩40.1b (down 27% from FY 2024). Profit margin: 9.4% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 10%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 31% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. New Risk • Mar 20
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.4% Last year net profit margin: 14% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Annuncio • Mar 13
Value Added Technology Co., Ltd., Annual General Meeting, Mar 26, 2026 Value Added Technology Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 13, samsung 1-ro 2-gil, gyeonggi-do, hwaseong South Korea New Risk • Mar 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Feb 27
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₩27,350, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total loss to shareholders of 18% over the past three years. Annuncio • Feb 14
Value Added Technology Co., Ltd. to Report Fiscal Year 2025 Results on Feb 19, 2026 Value Added Technology Co., Ltd. announced that they will report fiscal year 2025 results on Feb 19, 2026 Upcoming Dividend • Dec 22
Upcoming dividend of ₩100.00 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 17 April 2026. Payout ratio is a comfortable 3.0% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.1%). Declared Dividend • Nov 08
Dividend of ₩100.00 announced Dividend of ₩100.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 17th April 2026 Dividend yield will be 0.5%, which is lower than the industry average of 1.8%. Payout Ratios Payout ratio: 3%. Cash payout ratio: 4%. Annuncio • Nov 07
Value Added Technology Co., Ltd. announces Annual dividend, payable on April 17, 2026 Value Added Technology Co., Ltd. announced Annual dividend of KRW 100.0000 per share payable on April 17, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Major Estimate Revision • Aug 14
Consensus EPS estimates fall by 15% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩3,381 to ₩2,876. Revenue forecast unchanged from ₩416.7m at last update. Net income forecast to shrink 7.6% next year vs 56% growth forecast for Medical Equipment industry in South Korea . Consensus price target broadly unchanged at ₩29,125. Share price fell 4.0% to ₩22,950 over the past week. Annuncio • Aug 07
Value Added Technology Co., Ltd. to Report Q2, 2025 Results on Aug 11, 2025 Value Added Technology Co., Ltd. announced that they will report Q2, 2025 results on Aug 11, 2025 Annuncio • Aug 05
Vatech Introduces 'Clever One' - A Game-Changing Dental Viewer Solution for the U.S. Market Vatech has officially launched 'Vatech®? Clever One', its next-generation all-in-one dental platform, in the United States. Following FDA clearance of its AI-based lesion detection feature, the company now offers U.S. dental professionals a unified diagnostic environment designed to streamline every step of the clinical workflow--from image acquisition and simulation to patient communication. Clever One enables the integration of panoramic, CBCT, intraoral, facial, and STL scan data within a singleviewer. Its intuitive interface eliminates the need to switch between multiple software systems, helping dental professionals save time, reduce diagnostic complexity, and improve treatment predictability. Key features include: AI Lesion Detection: Automatically identifies potential lesions in panoramic images to support faster, more accurate screening; 3D Segmentation: One-click separation of teeth and bone structures enhances visualization for implantology and endodontics; Root Canal Analysis Tools: Assist measure root canal length and diameter, supporting precise endodontic planning; Image Alignment Support: Drag-and-drop functionality aligns CBCT, IOS, and facial scans in seconds; Implant and Endo Simulations: Advanced tools assist with preoperative planning for clinical decisions; Dual Scan Comparison: Allows clinicians to visualize changes before and after treatment; Scenario-Based UI/UX: Interface is structured to reflect real clinical workflows--diagnosis, comparison, consultation; Cloud Integration: Seamlessly syncs with EzCloud for data sharing and collaborative case management. The AI technology behind Clever One was developed through strategic partnerships with leading dental software and AI firms, including Pearl. These collaborations allow the platform to offer highly accurate segmentation, real-time lesion detection, and automated data management features--all tailored to clinical realities. Clever One also emphasizes user-centric design, allowing practitioners to configure toolbars, customize layouts, and adapt to various clinical setups, whether on chairside touchscreens or diagnostic workstations. The platform's responsive UI ensures compatibility across different resolutions and operating environments. With the introduction of Clever One, Vatech reinforces its commitment to shaping the future of digital dentalistry--where all diagnostic, planning, and communication processes are integrated into one intelligent and efficient platform. Major Estimate Revision • May 17
Consensus EPS estimates fall by 11% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩3,796 to ₩3,381 per share. Revenue forecast steady at ₩415.1m. Net income forecast to shrink 8.9% next year vs 26% growth forecast for Medical Equipment industry in South Korea . Consensus price target down from ₩30,000 to ₩29,000. Share price was steady at ₩20,000 over the past week. Reported Earnings • Mar 20
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: EPS: ₩3,712 (up from ₩3,483 in FY 2023). Revenue: ₩385.2b (flat on FY 2023). Net income: ₩55.1b (up 6.6% from FY 2023). Profit margin: 14% (in line with FY 2023). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Annuncio • Mar 13
Value Added Technology Co., Ltd., Annual General Meeting, Mar 26, 2025 Value Added Technology Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 13, samsung 1-ro 2-gil, gyeonggi-do, hwaseong South Korea Price Target Changed • Feb 19
Price target decreased by 7.0% to ₩30,833 Down from ₩33,167, the current price target is an average from 6 analysts. New target price is 50% above last closing price of ₩20,600. Stock is down 32% over the past year. The company is forecast to post earnings per share of ₩3,336 for next year compared to ₩3,483 last year. Annuncio • Feb 14
Value Added Technology Co., Ltd. to Report Q4, 2024 Results on Feb 17, 2025 Value Added Technology Co., Ltd. announced that they will report Q4, 2024 results on Feb 17, 2025 Upcoming Dividend • Dec 20
Upcoming dividend of ₩100.00 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 18 April 2025. Payout ratio is a comfortable 3.5% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.4%). Reported Earnings • Nov 20
Third quarter 2024 earnings released: EPS: ₩479 (vs ₩1,187 in 3Q 2023) Third quarter 2024 results: EPS: ₩479 (down from ₩1,187 in 3Q 2023). Revenue: ₩87.3b (flat on 3Q 2023). Net income: ₩7.11b (down 60% from 3Q 2023). Profit margin: 8.2% (down from 20% in 3Q 2023). Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Major Estimate Revision • Nov 15
Consensus EPS estimates fall by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩404.9m to ₩393.4m. EPS estimate also fell from ₩3,890 per share to ₩3,414 per share. Net income forecast to grow 4.6% next year vs 30% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩37,833 to ₩34,000. Share price fell 10% to ₩20,250 over the past week. Annuncio • Nov 05
Value Added Technology Co., Ltd. to Report Nine Months, 2024 Final Results on Nov 07, 2024 Value Added Technology Co., Ltd. announced that they will report nine months, 2024 final results on Nov 07, 2024 Price Target Changed • Aug 13
Price target decreased by 9.4% to ₩40,000 Down from ₩44,143, the current price target is an average from 7 analysts. New target price is 60% above last closing price of ₩25,000. Stock is down 32% over the past year. The company is forecast to post earnings per share of ₩3,804 for next year compared to ₩3,483 last year. Reported Earnings • Mar 24
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: ₩3,483 (down from ₩5,176 in FY 2022). Revenue: ₩384.9b (down 2.6% from FY 2022). Net income: ₩51.7b (down 33% from FY 2022). Profit margin: 13% (down from 20% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 24%. Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Price Target Changed • Feb 06
Price target decreased by 7.1% to ₩44,571 Down from ₩48,000, the current price target is an average from 7 analysts. New target price is 47% above last closing price of ₩30,300. Stock is down 12% over the past year. The company is forecast to post earnings per share of ₩4,586 for next year compared to ₩5,176 last year. Upcoming Dividend • Dec 20
Upcoming dividend of ₩100.00 per share at 0.3% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Payout ratio is a comfortable 2.3% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%). New Risk • Jul 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change). Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩39,600, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 95% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩71,247 per share. Reported Earnings • May 21
First quarter 2023 earnings released: EPS: ₩970 (vs ₩963 in 1Q 2022) First quarter 2023 results: EPS: ₩970 (up from ₩963 in 1Q 2022). Revenue: ₩91.0b (up 5.8% from 1Q 2022). Net income: ₩14.4b (flat on 1Q 2022). Profit margin: 16% (in line with 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 16
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩36,050, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 52% over the past three years. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩39,600, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 74% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩72,614 per share. Reported Earnings • Mar 26
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: EPS: ₩5,176 (up from ₩3,449 in FY 2021). Revenue: ₩395.1b (up 17% from FY 2021). Net income: ₩76.9b (up 50% from FY 2021). Profit margin: 20% (up from 15% in FY 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) exceeded analyst estimates by 9.7%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Price Target Changed • Feb 02
Price target decreased by 11% to ₩47,640 Down from ₩53,250, the current price target is an average from 5 analysts. New target price is 36% above last closing price of ₩34,950. Stock is up 4.3% over the past year. The company is forecast to post earnings per share of ₩4,629 for next year compared to ₩3,449 last year. Upcoming Dividend • Dec 21
Upcoming dividend of ₩100.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Payout ratio is a comfortable 2.2% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.8%). Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Major Estimate Revision • Nov 10
Consensus EPS estimates increase by 13% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from ₩387.8m to ₩400.7m. EPS estimate increased from ₩4,461 to ₩5,053 per share. Net income forecast to grow 10% next year vs 22% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩50,500 unchanged from last update. Share price rose 4.0% to ₩32,250 over the past week. Price Target Changed • Aug 19
Price target decreased to ₩53,250 Down from ₩57,575, the current price target is an average from 4 analysts. New target price is 58% above last closing price of ₩33,800. Stock is down 18% over the past year. The company is forecast to post earnings per share of ₩4,443 for next year compared to ₩3,449 last year. Major Estimate Revision • Aug 11
Consensus EPS estimates increase by 14% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from ₩381.9m to ₩391.0m. EPS estimate increased from ₩4,032 to ₩4,587 per share. Net income forecast to grow 32% next year vs 24% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩57,075 unchanged from last update. Share price rose 11% to ₩36,000 over the past week. Price Target Changed • Apr 27
Price target increased to ₩57,575 Up from ₩43,500, the current price target is an average from 4 analysts. New target price is 39% above last closing price of ₩41,300. Stock is up 32% over the past year. The company is forecast to post earnings per share of ₩4,206 for next year compared to ₩3,449 last year. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Upcoming Dividend • Dec 22
Upcoming dividend of ₩100.00 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.7%). Is New 90 Day High Low • Mar 11
New 90-day high: ₩27,100 The company is up 16% from its price of ₩23,450 on 11 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩47,930 per share. Is New 90 Day High Low • Jan 25
New 90-day high: ₩25,350 The company is up 19% from its price of ₩21,350 on 27 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩34,297 per share. Is New 90 Day High Low • Jan 05
New 90-day high: ₩24,600 The company is up 10.0% from its price of ₩22,450 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩34,363 per share. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩100.00 Per Share Will be paid on the 10th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.4% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.7%). Is New 90 Day High Low • Dec 03
New 90-day high: ₩23,550 The company is up 5.0% from its price of ₩22,500 on 04 September 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩28,964 per share. Is New 90 Day High Low • Oct 30
New 90-day low: ₩20,600 The company is down 13% from its price of ₩23,750 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩38,376 per share. Major Estimate Revision • Sep 19
Analysts lower EPS estimates to ₩1,453 The 2020 consensus revenue estimate was lowered from ₩248.3m to ₩229.1m. Earning per share (EPS) estimate was also lowered from ₩1,896 to ₩1,453 for the same period. Net income is expected to grow by 56% next year compared to 48% growth forecast for the Medical Equipment industry in South Korea. The consensus price target of ₩30,500 was unchanged from the last update. Share price stayed mostly flat at ₩23,050 over the past week.